FA
AMPH icon

Friess Associates’s Amphastar Pharmaceuticals AMPH Stock Holding History

Friess Associates’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$3.4M Sell
97,760
-56,655
-37% -$2.02M 5.68% 1
2022
Q1 		$5.54M Buy
+154,415
New +$4.38M 2.96% 4

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Friess Associates's AMPH Position: Q2 2022 in Review

Friess Associates reduced its Amphastar Pharmaceuticals (AMPH) stake by 37% in Q2 2022, selling an estimated $2.02M and leaving 97,760 shares worth $3.4M. The position accounts for 5.68% of the portfolio, ranked #1.

Friess Associates first reported a position in AMPH in Q1 2022 and has held it in 2 quarters since. The position peaked at $5.54M in Q1 2022. 222 funds tracked by Wall St. Rank hold AMPH as of Q2 2022.

  • Friess Associates held 97,760 shares of Amphastar Pharmaceuticals worth $3.4M as of Q2 2022.
  • Friess Associates sold 56,655 Amphastar Pharmaceuticals shares in Q2 2022, an estimated $2.02M.
  • Amphastar Pharmaceuticals made up 5.68% of Friess Associates's portfolio in Q2 2022, its #1 holding.
  • Friess Associates first reported a position in Amphastar Pharmaceuticals in Q1 2022 and has held it in 2 quarters since.
  • Friess Associates's Amphastar Pharmaceuticals position peaked at $5.54M in Q1 2022.
  • 222 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2022.

Based on Friess Associates's 13F filing for Q2 2022, filed 15 Aug 2022.